Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 18Radiotherapy 11Magnetic Resonance Spectroscopy 11Specimen Handling 8Radiation 7Lomustine 4Nivolumab 3Biopsy 3trametinib 2rocakinogene sifuplasmid 2dabrafenib 2cemiplimab 2Receptors, Interleukin-8B 2Photons 2Palliative Care 2Ipilimumab 2CTLA-4 Antigen 2vocimagene amiretrorepvec 1veliparib 1varlilumab 1tinostamustine 1temsirolimus 1senicapoc 1selinexor 1relatlimab 1regorafenib 1perampanel 1peposertib 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Vorinostat × 30 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡